Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

NCT04780516 · clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
141
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie